Guideline-directed medical therapy for heart failure was optimized at the time of discharge Beta-blockers; pre-admission 49 (61.25%), at discharge 57 (73.08%), angiotensin-converting enzyme inhibitor, angiotensin renin blocker or angiotensin receptor/neprilysin inhibitor; pre-admission 48.75%, at discharge 55.13%, diuretic; pre-admission 65%, at discharge 88.46%, MRA; pre-admission 23.75%, at discharge 47.44%, SGLT2i; pre-admission 3.75%, at discharge 23.08%. The gene discussed is MME; the disease is heart failure.